Maria Hafez, MD, discusses differences in biomarker expression prior to and following neoadjuvant chemotherapy treatment in HER2-positive breast cancer.
Maria Hafez, MD, discusses how hormone receptor status, risk stratification, and other disease factors influence the treatment decision-making process in patients with early-stage HER2-positive breast cancer.
Heather Han, MD, discusses initial safety and efficacy results from the phase 2 NATASHA trial in patients with early-stage HER2-positive breast cancer.
Suzanne B. Coopey, MD, FACS, discusses the de-escalation of axillary lymph node surgery, shifts in the use of radiation oncology, and changes in the treatment paradigm for HER2-positive breast cancer.